Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.
Elicera Therapeutics AB (publ) ("Elicera" or the "Company") has received additional subscription commitments from members of the board and management in the ongoing rights issue. Jamal El-Mosleh and Di Yu intend to increase their subscription by SEK 100,000 each, and Jan Zetterberg intends to subscribe for SEK 230,000.
On 20 February 2024 the extraordinary general meeting of the Company resolved on a rights issue of units of approximately SEK 64 million (the "Rights Issue"). The subscription period in the Rights Issue started on 23 February 2024 and ends 8 March 2024. Elicera has received additional subscription commitments from the following members of the board and management who intend to subscribe in the Rights Issue:
Shareholder Role in the Company Initial Increased commitment, SEK
commitment,
SEK
Jamal El CEO 250,000 100,000
-Mosleh
Di Yu Head of Translational 100,000 100,000
Research and co-fonder
Jan Board member 0 230,000
Zetterberg
Total 350,000 430,000
Through these subscription commitments, the board and management demonstrate their continued confidence in Elicera's future prospects. Overall the subscription commitments from the board and management amount to approximately 1 million SEK.